Bicara Therapeutics Common Stock Net Asset
| BCAX Stock | 12.33 0.12 0.96% |
Bicara Therapeutics Common fundamentals help investors to digest information that contributes to Bicara Therapeutics' financial success or failures. It also enables traders to predict the movement of Bicara Stock. The fundamental analysis module provides a way to measure Bicara Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bicara Therapeutics stock.
Bicara |
Bicara Therapeutics Common Company Net Asset Analysis
Bicara Therapeutics' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Bicara Therapeutics Net Asset | 233.98 M |
Most of Bicara Therapeutics' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bicara Therapeutics Common is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Bicara Net Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Bicara Therapeutics is extremely important. It helps to project a fair market value of Bicara Stock properly, considering its historical fundamentals such as Net Asset. Since Bicara Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Bicara Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Bicara Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Bicara Total Assets
Total Assets |
|
Based on the recorded statements, Bicara Therapeutics Common has a Net Asset of 233.98 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Bicara Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bicara Therapeutics' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bicara Therapeutics could also be used in its relative valuation, which is a method of valuing Bicara Therapeutics by comparing valuation metrics of similar companies.Bicara Therapeutics is currently under evaluation in net asset category among its peers.
Bicara Fundamentals
| Current Valuation | 577.25 M | ||||
| Shares Outstanding | 54.39 M | ||||
| Shares Owned By Insiders | 0.42 % | ||||
| Number Of Shares Shorted | 4.08 M | ||||
| Price To Book | 2.15 X | ||||
| EBITDA | (51.96 M) | ||||
| Net Income | (51.98 M) | ||||
| Total Debt | 657 K | ||||
| Book Value Per Share | (5.10) X | ||||
| Cash Flow From Operations | (45.63 M) | ||||
| Earnings Per Share | (3.75) X | ||||
| Market Capitalization | 1.1 B | ||||
| Total Asset | 233.98 M | ||||
| Retained Earnings | (153.02 M) | ||||
| Working Capital | 215.99 M | ||||
| Net Asset | 233.98 M |
About Bicara Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bicara Therapeutics Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bicara Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bicara Therapeutics Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Bicara Stock Analysis
When running Bicara Therapeutics' price analysis, check to measure Bicara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bicara Therapeutics is operating at the current time. Most of Bicara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Bicara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bicara Therapeutics' price. Additionally, you may evaluate how the addition of Bicara Therapeutics to your portfolios can decrease your overall portfolio volatility.